Guggenheim raised the firm’s price target on Praxis Precision (PRAX) to $350 from $155 and keeps a Buy rating on the shares following two positive pivotal trial readouts for ulixacaltamide in essential tremor. Given the unmet need and “robustness” of the data, the firm estimates the ET opportunity to be worth over $2B in the U.S. and it assumes 80% odds of potential approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Why Is Praxis Precision Medicines (PRAX) Stock Up 155% Today?
- Praxis Precision Medicines Announces Positive Phase 3 Results
- Praxis Precision announces results from two Phase 3 studies of ulixacaltamide
- 3 Best Stocks to Buy Now, 9/22/2025, According to Top Analysts
- Praxis Precision initiated with a Buy at JonesResearch